CN102144036B - 用于乳腺癌风险评估的遗传变型 - Google Patents

用于乳腺癌风险评估的遗传变型 Download PDF

Info

Publication number
CN102144036B
CN102144036B CN200980134453.0A CN200980134453A CN102144036B CN 102144036 B CN102144036 B CN 102144036B CN 200980134453 A CN200980134453 A CN 200980134453A CN 102144036 B CN102144036 B CN 102144036B
Authority
CN
China
Prior art keywords
risk
breast cancer
markers
marker
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980134453.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102144036A (zh
Inventor
S·斯达赛
P·苏勒姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of CN102144036A publication Critical patent/CN102144036A/zh
Application granted granted Critical
Publication of CN102144036B publication Critical patent/CN102144036B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00Subject matter not provided for in other groups of this subclass
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60In silico combinatorial chemistry
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Library & Information Science (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200980134453.0A 2008-07-07 2009-07-03 用于乳腺癌风险评估的遗传变型 Expired - Fee Related CN102144036B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8746 2008-07-07
IS8746 2008-07-07
PCT/IS2009/000008 WO2010004591A2 (en) 2008-07-07 2009-07-03 Genetic variants for breast cancer risk assessment

Publications (2)

Publication Number Publication Date
CN102144036A CN102144036A (zh) 2011-08-03
CN102144036B true CN102144036B (zh) 2014-07-16

Family

ID=41110719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980134453.0A Expired - Fee Related CN102144036B (zh) 2008-07-07 2009-07-03 用于乳腺癌风险评估的遗传变型

Country Status (10)

Country Link
US (1) US8951735B2 (enExample)
EP (1) EP2313525A2 (enExample)
JP (1) JP2011527565A (enExample)
KR (1) KR20110036608A (enExample)
CN (1) CN102144036B (enExample)
AU (1) AU2009269542A1 (enExample)
CA (1) CA2729934A1 (enExample)
IL (1) IL210504A0 (enExample)
NZ (1) NZ590833A (enExample)
WO (1) WO2010004591A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095999A1 (en) * 2010-02-05 2011-08-11 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
HK1197085A1 (en) * 2011-06-16 2015-01-02 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
CN102643905B (zh) * 2012-04-01 2014-06-11 周宏灏 焦磷酸测序法检测他莫昔芬个体化用药基因多态性的试剂盒及方法
KR101770962B1 (ko) * 2013-02-01 2017-08-24 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014119914A1 (ko) * 2013-02-01 2014-08-07 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN103981273B (zh) * 2014-05-30 2017-01-18 复旦大学附属肿瘤医院 一组评估乳腺癌风险的突变基因群及其检测试剂盒
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN105069322B (zh) * 2015-07-24 2018-01-12 上海尔云信息科技有限公司 疾病易感风险预测装置
US12071669B2 (en) 2016-02-12 2024-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
CN105586427B (zh) * 2016-03-10 2020-06-19 厦门艾德生物医药科技股份有限公司 检测人类brca1和brca2基因突变的引物、试剂盒及方法
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CN106676169B (zh) * 2016-11-15 2021-01-12 上海派森诺医学检验所有限公司 一种用于乳腺癌易感基因brca1和brca2突变检测的杂交捕获试剂盒及其方法
CN110382712A (zh) * 2017-01-24 2019-10-25 基因技术有限公司 用于评估发展乳腺癌的风险的改进方法
CN107341347A (zh) * 2017-06-27 2017-11-10 天方创新(北京)信息技术有限公司 基于评分模型对乳腺癌进行风险评分的方法及装置
US11674187B2 (en) * 2018-06-29 2023-06-13 The Jackson Laboratory Breast cancer splice variants
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
EP4139508A4 (en) * 2020-04-20 2024-08-28 Myriad Genetics, Inc. COMPREHENSIVE POLYGENIC RISK PREDICTION FOR BREAST CANCER
WO2024085660A1 (ko) * 2022-10-18 2024-04-25 제노플랜 인크 질병 발생 위험도 예측 장치 및 방법
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662661A (zh) * 2002-06-18 2005-08-31 英维泰克生物技术和生物设计有限公司 肿瘤易感性增加的检测方法
CN1696154A (zh) * 2004-02-20 2005-11-16 三星电子株式会社 乳腺癌相关蛋白、编码该蛋白的基因和诊断乳腺癌的方法
WO2006063285A2 (en) * 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
CN101037690A (zh) * 2006-03-16 2007-09-19 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69527585T2 (de) 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
EP0912761A4 (en) 1996-05-29 2004-06-09 Cornell Res Foundation Inc DETERMINATION OF DIFFERENCES IN THE NUCLEIC ACID SEQUENCE BY MEANS OF A COMBINATION OF LIGASE DETERMINATION AND POLYMERASE CHAIN REACTION
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
SG175680A1 (en) * 2006-10-27 2011-11-28 Decode Genetics Ehf Cancer susceptibility variants on chr8q24.21
AU2008231425B2 (en) 2007-03-26 2014-03-20 Decode Genetics Ehf Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EA018444B1 (ru) 2007-05-25 2013-08-30 Декоуд Дженетикс Ехф. ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr 5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662661A (zh) * 2002-06-18 2005-08-31 英维泰克生物技术和生物设计有限公司 肿瘤易感性增加的检测方法
CN1696154A (zh) * 2004-02-20 2005-11-16 三星电子株式会社 乳腺癌相关蛋白、编码该蛋白的基因和诊断乳腺癌的方法
WO2006063285A2 (en) * 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
CN101037690A (zh) * 2006-03-16 2007-09-19 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
rs999737;登录号;《NCBI,dbSNP》;20000907;全文 *

Also Published As

Publication number Publication date
JP2011527565A (ja) 2011-11-04
IL210504A0 (en) 2011-03-31
KR20110036608A (ko) 2011-04-07
CN102144036A (zh) 2011-08-03
CA2729934A1 (en) 2010-01-14
WO2010004591A3 (en) 2010-03-18
EP2313525A2 (en) 2011-04-27
WO2010004591A2 (en) 2010-01-14
NZ590833A (en) 2013-01-25
US20110294673A1 (en) 2011-12-01
AU2009269542A1 (en) 2010-01-14
US8951735B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
CN102144036B (zh) 用于乳腺癌风险评估的遗传变型
US8580501B2 (en) Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CN102177252B (zh) 用于甲状腺癌症的风险评估的遗传变型
JP5631000B2 (ja) Chr8q24.21上の癌感受性変異体
JP5676245B2 (ja) 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのchr2およびchr16の遺伝的変異
CN102137937A (zh) 作为用于膀胱癌风险评估、诊断、预后和治疗的标志的遗传变型
WO2010004589A2 (en) Genetic variants predictive of cancer risk in humans
US20110020320A1 (en) Genetic Variants Contributing to Risk of Prostate Cancer
WO2013065072A1 (en) Risk variants of prostate cancer
US20140248615A1 (en) Genetic variants on chr 11q and 6q as markers for prostate and colorectal cancer predisposition
US20120225786A1 (en) Risk variants for cancer
WO2010131268A1 (en) Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma
WO2011095999A1 (en) Genetic variants for predicting risk of breast cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716

Termination date: 20150703

EXPY Termination of patent right or utility model